Amgen (AMGN) Stock Forecast, Price & News

Amgen (NASDAQ:AMGN) Frequently Asked Questions

Is Amgen a buy right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 1 sell rating, 10 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Amgen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View analyst ratings for Amgen or view top-rated stocks.

When is Amgen's next earnings date?

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Amgen.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings data on Wednesday, April, 27th. The medical research company reported $4.25 earnings per share for the quarter, beating analysts' consensus estimates of $4.22 by $0.03. The medical research company earned $6.24 billion during the quarter, compared to analyst estimates of $6.09 billion. Amgen had a net margin of 21.75% and a trailing twelve-month return on equity of 165.95%. During the same quarter in the prior year, the company posted $3.70 earnings per share.
View Amgen's earnings history.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Wednesday, March 2nd. Stockholders of record on Tuesday, May 17th will be paid a dividend of $1.94 per share on Wednesday, June 8th. This represents a $7.76 dividend on an annualized basis and a yield of 3.05%. The ex-dividend date of this dividend is Monday, May 16th.
View Amgen's dividend history.

Is Amgen a good dividend stock?

Amgen pays an annual dividend of $7.76 per share and currently has a dividend yield of 3.07%. Amgen has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Amgen is 76.38%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, Amgen will have a dividend payout ratio of 40.89% next year. This indicates that Amgen will be able to sustain or increase its dividend.
View Amgen's dividend history.

What guidance has Amgen issued on next quarter's earnings?

Amgen updated its FY22 earnings guidance on Wednesday, April, 27th. The company provided earnings per share (EPS) guidance of $17.00-18.00 for the period, compared to the consensus earnings per share estimate of $17.61. The company issued revenue guidance of $25.4-26.5 billion, compared to the consensus revenue estimate of $26.09 billion.

What price target have analysts set for AMGN?

14 Wall Street analysts have issued 1 year price targets for Amgen's stock. Their forecasts range from $185.00 to $285.00. On average, they expect Amgen's stock price to reach $242.21 in the next year. This suggests that the stock has a possible downside of 4.9%.
View analysts' price targets for Amgen or view top-rated stocks among Wall Street analysts.

Who are Amgen's key executives?

Amgen's management team includes the following people:

• Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 59, Pay $5.81M)
• Mr. Peter H. Griffith, Exec. VP & CFO (Age 63, Pay $2.66M)
• Mr. Esteban Santos, Exec. VP of Operations (Age 54, Pay $2.61M)
• Dr. David M. Reese M.D., Exec. VP of R&D (Age 59, Pay $2.79M)
• Mr. Murdo Gordon, Exec. VP of Global Commercial Operations (Age 55, Pay $2.82M)
• Ms. Linda H. Louie, VP of Fin. & Chief Accounting Officer
• Mr. Mike Zahigian, Sr. VP & Chief Information Officer
• Mr. Arvind Sood, VP of Investor Relations
• Mr. Jonathan P. Graham, Exec. VP, Gen. Counsel & Sec. (Age 61) (LinkedIn Profile)
• Ms. Nancy A. Grygiel, Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer (Age 54) (LinkedIn Profile)

What is Robert A. Bradway's approval rating as Amgen's CEO?

806 employees have rated Amgen CEO Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among Amgen's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amgen's key competitors?

Some companies that are related to Amgen include Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Exact Sciences (EXAS), Repligen (RGEN), Neurocrine Biosciences (NBIX), Halozyme Therapeutics (HALO), Exelixis (EXEL) and Ionis Pharmaceuticals (IONS).
View all of AMGN's competitors.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.37%), Vanguard Group Inc. (8.86%), State Street Corp (5.71%), Capital Research Global Investors (3.45%), Primecap Management Co. CA (2.94%) and Charles Schwab Investment Management Inc. (1.65%). Company insiders that own Amgen stock include Jonathan P Graham, Jonathan P Graham, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends for Amgen.

Which institutional investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Capital International Investors, Healthcare of Ontario Pension Plan Trust Fund, Renaissance Technologies LLC, Nordea Investment Management AB, Capitolis Advisors LLC, Bank of Nova Scotia, and Toronto Dominion Bank. Company insiders that have sold Amgen company stock in the last year include Jonathan P Graham, and R Sanders Williams.
View insider buying and selling activity for Amgen or view top insider-selling stocks.

Which institutional investors are buying Amgen stock?

AMGN stock was acquired by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Aaron Wealth Advisors LLC, Arrowstreet Capital Limited Partnership, Vanguard Group Inc., State Street Corp, Invesco Ltd., Verity Asset Management Inc., and Swiss National Bank.
View insider buying and selling activity for Amgen or or view top insider-buying stocks.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $254.72.

How much money does Amgen make?

Amgen has a market capitalization of $136.07 billion and generates $25.98 billion in revenue each year. The medical research company earns $5.89 billion in net income (profit) each year or $10.16 on an earnings per share basis.

How many employees does Amgen have?

Amgen employs 24,200 workers across the globe.

Does Amgen have any subsidiaries?

The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc..

When was Amgen founded?

Amgen was founded in 1980.

What is Amgen's official website?

The official website for Amgen is www.amgen.com.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at (805) 447-1000, via email at [email protected], or via fax at 805-447-1010.